TriSalus Life Sciences, Inc.

TLSI · Nasdaq · SIC 3841: Surgical & Medical Instruments & Apparatus · Market Cap: $0.3B · 102 employees
128
SEC Filings
$3.67
Close 2026-06-01
102
Employees

Business Summary

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that develops innovative drug delivery technologies for solid tumors. Its flagship product, the TriNav Infusion System, uses Pressure-Enabled Drug Delivery (PEDD) technology for interventional radiology procedures including TACE and TARE. The company also develops nelitolimod, an investigational TLR9 agonist, and the PRVI device for pancreatic tumor treatment, generating $45.2 million in TriNav revenue in 2025.

Latest Stock Quote

TLSI 2026-06-01 $3.67 O:$3.4 H:$3.68 L:$3.26 Vol:0.3M VWAP:$3.5186
origin leaf: 3215ab609291acd2fe5ef9f2a8b5381c83d6f4f9fe79a643a96716d294394b5e

Next Earnings

Q2 FY2026 — expected 2026-09-23

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-052025-12-310001628280-26-015163EDGAR85K words
2025-04-152024-12-310001826667-25-000030EDGAR
2024-04-112023-12-310001826667-24-000005EDGAR
2023-03-222022-12-310001410578-23-000332EDGAR
2022-03-032021-12-310001410578-22-000252EDGAR
2021-03-312020-12-310001104659-21-044719EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001628280-25-052043EDGAR25K words
2025-08-122025-06-300001826667-25-000117EDGAR
2025-05-152025-03-310001826667-25-000051EDGAR
2024-11-142024-09-300001826667-24-000051EDGAR
2024-08-142024-06-300001826667-24-000039EDGAR
2024-05-152024-03-310001826667-24-000017EDGAR
2023-11-142023-09-300001826667-23-000007EDGAR
2023-08-022023-06-300001410578-23-001525EDGAR
2023-05-122023-03-310001410578-23-001035EDGAR
2022-11-102022-09-300001410578-22-003118EDGAR
2022-08-102022-06-300001410578-22-002206EDGAR
2022-05-112022-03-310001410578-22-001311EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-050001628280-26-015155EDGAR5K words
2026-02-200001493152-26-007598EDGAR
2026-02-090001628280-26-006219EDGAR
2026-01-120001628280-26-001743EDGAR
2025-11-130001628280-25-052008EDGAR
2025-10-010001628280-25-043440EDGAR
2025-08-290001826667-25-000129EDGAR
2025-08-120001826667-25-000115EDGAR
2025-07-240001826667-25-000103EDGAR
2025-06-230001826667-25-000077EDGAR

128 total filings indexed. 100 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

MMM — 3M CO ARAY — ACCURAY INC AEMD — AETHLON MEDICAL INC ALUR — ALLURION TECHNOLOGIES, INC. ANGO — ANGIODYNAMICS INC AORT — ARTIVION, INC. RCEL — AVITA Medical, Inc. ADGM — Adagio Medical Holdings, Inc.

Tags

oncology---liver-cancer-(hcc,-icc,-liver-metastases) oncology---pancreatic-cancer-(pdac) interventional-radiology uterine-artery-embolization thyroid-artery-embolization prostate-embolization genicular-artery-embolization-for-osteoarthritis fda-510(k)-clearance toll-like-receptor-9-(tlr9)-agonist-platform immune-checkpoint-inhibitor-(cpi)-combination-therapy

Company Identity

CIK0001826667
TickerTLSI
ExchangeNasdaq
SIC3841: Surgical & Medical Instruments & Apparatus
IncorporatedDE
Websitehttps://www.trisaluslifesci.com
Listed2023-08-11

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a9169482fdd6f6d30b110de5981f620b7b680fcc459bc82688150782d63506a2
parent: 43ea66ad1f9c8e9762e5a86fef5f83b2561132e8e11777f01fb211b6f134f8a0
content hash: d0c2360bd72276b50f4e52c3ae9ecc32f2a6c6d45569c575673f9f2b5863aefd
signed: 2026-06-02T19:02:51.465Z
sources: 19 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf